Table 2.

Associations by family history, synchronous or metachronous bilateral disease, age at diagnosis and hormone receptor subtype.

		ATM			CHEK2			PALB2
	All Cases	Carriers	OR (95%CI)	P-Value	Carriers	OR (95%CI)	P-Value	Carriers	OR (95%CI)	P-Value
Family History*
Positive	1301 (17.0%)	16 (29.6%)			28 (23.5%)			7 (13.2%)
Negative	6330 (83.0%)	38 (70.4%)	2.06 (1.12–3.65)	0.022	91 (76.5%)	1.51 (0.97–2.28)	0.070	46 (86.8%)	0.74 (0.60–1.54)	0.44
Bilateral Disease*
Positive	220 (1.7%)	0 (0.0%)			11 (5.3%)			4 (4.7%)
Negative	12 526 (98.3%)	83 (100.0%)	NA	0.089	198 (94.7%)	3.27 (1.66–5.83)	0.0014	81 (95.3%)	2.85 (0.86–6.91)	0.080
Age at Diagnosis*
Before 50	3674 (28.4%)	25 (29.8%)	3.41 (1.72–7.23)		76 (36.0%)	3.98 (2.62–6.21)		27 (31.4%)	5.80 (2.67–14.5)
50s	4952 (38.3%)	34 (40.5%)	3.44 (1.80–7.13)		87 (41.2%)	3.37 (2.24–5.22)		41 (47.7%)	6.54 (3.12–16.0)
After 60	4305 (33.3%)	25 (29.8%)	2.91 (1.47–6.17)	0.66	48 (22.7%)	2.12 (1.35–3.41)	1.2×10−5	18 (20.9%)	3.29 (1.43–8.47)	0.22
ER Status†
Positive	7845 (83.6%)	50 (92.6%)	3.19 (1.73–6.47)	1.0×10−4	140 (91.5%)	3.42 (2.33–5.21)	1.5×10−11	43 (79.6%)	4.32 (2.07–10.5)	2.7×10−5
Negative	1544 (16.4%)	4 (7.4%)	1.28 (0.36–3.76)	0.67	13 (8.5%)	1.59 (0.80–3.00)	0.18	11 (20.4%)	5.58 (2.19–15.2)	3.6×10−4
PR Status†
Positive	3026 (66.5%)	16 (64%)	2.65 (1.24–5.87)	0.012	61 (81.3%)	3.87 (2.51–6.12)	4.3E-10	16 (57.1%)	4.16 (1.77–10.8)	9.0×10−4
Negative	1524 (33.5%)	9 (36%)	2.96 (1.19–7.16)	0.021	14 (18.7%)	1.75 (0.89–3.25)	0.100	12 (42.9%)	6.21 (2.5–16.7)	1.0×10−4

*Case only analysis.

†Case-control analysis.